Search
Baili Tianheng: The Pioneer Subject Enrolled in the Phase III Trial of T-Bren for Breast Cancer Treatment
5 day ago /
Read about 0 minute
Author：小编
Baili Tianheng's self-developed injectable drug, T-Bren (an HER2 ADC), when used in conjunction with pertuzumab, has successfully enrolled its first subject in a Phase III randomized controlled clinical trial. This trial aims to compare the efficacy of T-Bren combined with pertuzumab against the standard regimen of docetaxel, carboplatin, trastuzumab, and pertuzumab in the neoadjuvant treatment of HER2-positive breast cancer. At present, T-Bren is actively involved in 20 clinical trials, both within China and internationally, exploring its potential across a range of tumor types.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
